Tenaya Therapeutics Inc
TNYA0.757USD
+0.057+8.08%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
123.97MMarket Cap
LossP/E TTM
More Details of Tenaya Therapeutics Inc Company
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Tenaya Therapeutics Inc Info
Ticker SymbolTNYA
Company nameTenaya Therapeutics Inc
IPO dateJul 30, 2021
CEOAli (Faraz)
Number of employees97
Security typeOrdinary Share
Fiscal year-endJul 30
Address171 Oyster Point Blvd., Suite 500
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone14158652066
Websitehttps://www.tenayatherapeutics.com/
Ticker SymbolTNYA
IPO dateJul 30, 2021
CEOAli (Faraz)
Company Executives of Tenaya Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
79.78K
-3.77%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. David V. Goeddel, Ph.D.
Dr. David V. Goeddel, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey T. (Jeff) Walsh
Mr. Jeffrey T. (Jeff) Walsh
Independent Director
Independent Director
--
--
Dr. Deepak Srivastava, M.D.
Dr. Deepak Srivastava, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
79.78K
-3.77%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Column Group LP
27.47%
The Vanguard Group, Inc.
2.37%
Empery Asset Management, L.P.
2.20%
Millennium Management LLC
2.11%
BlackRock Institutional Trust Company, N.A.
1.09%
Other
64.76%
Shareholders
Shareholders
Proportion
The Column Group LP
27.47%
The Vanguard Group, Inc.
2.37%
Empery Asset Management, L.P.
2.20%
Millennium Management LLC
2.11%
BlackRock Institutional Trust Company, N.A.
1.09%
Other
64.76%
Shareholder Types
Shareholders
Proportion
Venture Capital
27.94%
Investment Advisor
5.18%
Hedge Fund
4.25%
Investment Advisor/Hedge Fund
3.50%
Individual Investor
0.53%
Research Firm
0.31%
Private Equity
0.22%
Family Office
0.06%
Other
57.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
229
36.31M
22.28%
-78.17M
2025Q2
235
93.48M
57.36%
+20.23M
2025Q1
240
59.62M
37.68%
-6.11M
2024Q4
227
46.66M
58.78%
-21.29M
2024Q3
228
59.37M
75.30%
-7.13M
2024Q2
219
58.72M
74.83%
-7.58M
2024Q1
206
57.55M
73.35%
-12.34M
2023Q4
191
47.88M
70.30%
-10.62M
2023Q3
197
52.92M
79.61%
-6.27M
2023Q2
192
50.82M
77.84%
-5.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Column Group LP
9.40M
5.77%
-39.91M
-80.94%
Jun 30, 2025
The Vanguard Group, Inc.
4.76M
2.92%
+673.29K
+16.49%
Jun 30, 2025
Empery Asset Management, L.P.
4.71M
2.89%
-4.02M
-46.09%
Jun 30, 2025
Millennium Management LLC
680.74K
0.42%
+638.69K
+1518.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.67M
1.64%
-2.29M
-46.20%
Jun 30, 2025
Renaissance Technologies LLC
1.84M
1.13%
+302.15K
+19.60%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.23M
0.76%
-144.59K
-10.51%
Jun 30, 2025
Two Sigma Investments, LP
642.59K
0.39%
+223.16K
+53.21%
Jun 30, 2025
Euclidean Capital, L.L.C.
1.02M
0.62%
--
--
Jun 30, 2025
Alphabet, Inc.
915.71K
0.56%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Tema Heart & Health ETF
0%
iShares Health Innovation Active ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
View more
iShares Russell 2000 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Tema Heart & Health ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tenaya Therapeutics Inc?
The top five shareholders of Tenaya Therapeutics Inc are:
The Column Group LP holds 9.40M shares, accounting for 5.77% of the total shares.
The Vanguard Group, Inc. holds 4.76M shares, accounting for 2.92% of the total shares.
Empery Asset Management, L.P. holds 4.71M shares, accounting for 2.89% of the total shares.
Millennium Management LLC holds 680.74K shares, accounting for 0.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.67M shares, accounting for 1.64% of the total shares.
The Column Group LP holds 9.40M shares, accounting for 5.77% of the total shares.
The Vanguard Group, Inc. holds 4.76M shares, accounting for 2.92% of the total shares.
Empery Asset Management, L.P. holds 4.71M shares, accounting for 2.89% of the total shares.
Millennium Management LLC holds 680.74K shares, accounting for 0.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.67M shares, accounting for 1.64% of the total shares.
What are the top three shareholder types of Tenaya Therapeutics Inc?
The top three shareholder types of Tenaya Therapeutics Inc are:
The Column Group LP
The Vanguard Group, Inc.
Empery Asset Management, L.P.
The Column Group LP
The Vanguard Group, Inc.
Empery Asset Management, L.P.
How many institutions hold shares of Tenaya Therapeutics Inc (TNYA)?
As of 2025Q3, 229 institutions hold shares of Tenaya Therapeutics Inc, with a combined market value of approximately 36.31M, accounting for 22.28% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -35.08%.
What is the biggest source of revenue for Tenaya Therapeutics Inc?
In --, the -- business generated the highest revenue for Tenaya Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
